Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech
Yuhan ups investment in biotechs for immuno-oncology drug push
"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018
More than half of Korean biopharma firms view R&D investments as assets.
Oscotec shares rebound on launch of US clinical trial
INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs
Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money
G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
Profiles of Four New Stock-Billionaires
IPOs spawn instant billionaires